AUTL

Autolus Therapeutics Ltd is a London-based clinical-stage biopharmaceutical company dedicated to the development of cutting-edge T-cell therapies for cancer treatment. The company boasts a strong pipeline of proprietary technologies aimed at improving the safety and efficacy of cellular immunotherapies. With its innovative approach to harnessing T-cell capabilities, Autolus is strategically positioned to address significant unmet medical needs in oncology, making it a compelling prospect for institutional investors focused on advancements in cancer care.